Compare AREN & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AREN | UNCY |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.1M | 141.8M |
| IPO Year | 2017 | 2021 |
| Metric | AREN | UNCY |
|---|---|---|
| Price | $3.13 | $6.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $12.00 | ★ $44.50 |
| AVG Volume (30 Days) | 44.0K | ★ 480.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.25 |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $16,892,000.00 | $675,000.00 |
| Revenue This Year | $13.89 | N/A |
| Revenue Next Year | $13.81 | N/A |
| P/E Ratio | $1.22 | ★ N/A |
| Revenue Growth | ★ 27.46 | N/A |
| 52 Week Low | $1.40 | $0.45 |
| 52 Week High | $10.05 | $7.57 |
| Indicator | AREN | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 41.99 | 49.86 |
| Support Level | $3.07 | $5.90 |
| Resistance Level | $3.54 | $6.82 |
| Average True Range (ATR) | 0.21 | 0.36 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 46.63 | 41.59 |
The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The Company operates in one reportable segment which focuses on a publishing platform. The company generates revenue from Digital and Print, where the majority is generated from Digital. The company owns and operates TheStreet, The Spun, Parade, and Men's Journal and powers more than 320 independent Publisher Partners.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.